Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Casadei Gardini A, et al. Among authors: foschi fg. Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. Eur J Cancer. 2017. PMID: 28985579 Free article.
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients.
Gramenzi A, Tedeschi S, Cantarini MC, Erroi V, Tumietto F, Attard L, Calza L, Foschi FG, Caraceni P, Pavoni M, Cucchetti A, Bernardi M, Viale P, Verucchi G, Trevisani F. Gramenzi A, et al. Among authors: foschi fg. Dig Liver Dis. 2013 Jun;45(6):516-22. doi: 10.1016/j.dld.2012.12.010. Epub 2013 Jan 16. Dig Liver Dis. 2013. PMID: 23332770
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Giannini EG, et al. Among authors: foschi fg. Cancer. 2014 Jul 15;120(14):2150-7. doi: 10.1002/cncr.28706. Epub 2014 Apr 10. Cancer. 2014. PMID: 24723129 Free article.
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassineti GL. Casadei Gardini A, et al. Among authors: foschi fg. Expert Opin Pharmacother. 2015;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29. Expert Opin Pharmacother. 2015. PMID: 26513009 Free article.
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL. Casadei Gardini A, et al. Among authors: foschi fg. Oncotarget. 2016 Mar 22;7(12):15243-51. doi: 10.18632/oncotarget.7444. Oncotarget. 2016. PMID: 26893366 Free PMC article.
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL. Casadei Gardini A, et al. Among authors: foschi fg. Oncotarget. 2016 May 10;7(19):27988-99. doi: 10.18632/oncotarget.8569. Oncotarget. 2016. PMID: 27058899 Free PMC article.
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.
Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. Farinati F, et al. Among authors: foschi fg. PLoS Med. 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr. PLoS Med. 2016. PMID: 27116206 Free PMC article.
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL. Casadei Gardini A, et al. Among authors: foschi fg. Oncotarget. 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565. Oncotarget. 2016. PMID: 27613839 Free PMC article.
172 results